# Marc-Oliver Grimm

List of Publications by Year
in descending order



| 117 | 11,326 | 81743 39 | 30848 102 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 170 | 170 | 170 | 12602 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290. | 13.9 | 3,334 |
| 2 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2017, 18, 312-322. | 5.1 | 1,388 |
| 3 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385. | 5.1 | 594 |
| 4 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079. | 2.0 | 343 |
| 5 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1574-1588. | 5.1 | 324 |
| 6 | Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology, 2020, 31, 1030-1039. | 0.6 | 316 |
| 7 | IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDY. Journal of Urology, 2005, 174, 862-866. | 0.2 | 284 |
| 8 | The Contemporary Concept of Significant Versus Insignificant Prostate Cancer. European Urology, 2011, 60, 291-303. | 0.9 | 267 |
| 9 | Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treatment Reviews, 2017, 57, 36-49. | 3.4 | 257 |
| 10 | Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 297-310. | 5.1 | 207 |
| 11 | A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. European Urology, 2016, 69, 94-102. | 0.9 | 201 |
| 12 | A singleâ€arm, multicenter, openâ€label phase 2 study of lapatinib as the secondâ€line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer, 2009, 115, 2881-2890. | 2.0 | 196 |
| 13 | 180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trialâ€"The GOLIATH Study. European Urology, 2014, 65, 931-942. | 0.9 | 189 |
| 14 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891. | | 160 |
| 15 | An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 2021, 12, 2301. | 5.8 | 159 |
| 16 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277. | 6.3 | 153 |
| 17 | Assessment of PI-RADS v2 for the Detection of Prostate Cancer. European Journal of Radiology, 2016, 85, 726-731. | 1.2 | 141 |
| 18 | Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 0.9 | 117 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A European Multicenter Randomized Noninferiority Trial Comparing 180 W GreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study. Journal of Urology, 2015, 193, 570-578. | 0.2 | 117 |
| 20 | Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder. Clinical Cancer Research, 2004, 10, 3410-3421. | 3.2 | 110 |
| 21 | Conditional survival and longâ€term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 2022, 128, 2085-2097. | 2.0 | 103 |
| 22 | Gene signatures of pulmonary metastases of renal cell carcinoma reflect the diseaseâ€free interval and the number of metastases per patient. International Journal of Cancer, 2009, 125, 474-482. | 2.3 | 93 |
| 23 | Molecular Markers Increase Precision of the European Association of Urology Nonâ€“Muscle-Invasive Bladder Cancer Progression Risk Groups. Clinical Cancer Research, 2018, 24, 1586-1593. | 3.2 | 79 |
| 24 | Treatment of High-grade Nonâ€“muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial â€œNIMBUSâ€. European Urology, 2020, 78, 690-698. | 0.9 | 76 |
| 25 | Prognostic Impact of a 12-gene Progression Score in Nonâ€“muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. European Urology, 2017, 72, 461-469. | 0.9 | 74 |
| 26 | CD31, EDNRB and TSPAN7 are promising prognostic markers in clearâ€cell renal cell carcinoma revealed by genomeâ€wide expression analyses of primary tumors and metastases. International Journal of Cancer, 2012, 131, E693-704. | 2.3 | 72 |
| 27 | Catecholamines Relax Detrusor through Î²<sub>2</sub>-Adrenoceptors in Mouse and Î²<sub>3</sub>-Adrenoceptors in Man. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 213-222. | 1.3 | 69 |
| 28 | MicroRNAs with Prognostic Potential for Metastasis in Clear Cell Renal Cell Carcinoma: A Comparison of Primary Tumors and Distant Metastases. Annals of Surgical Oncology, 2014, 21, 1046-1054. | 0.7 | 64 |
| 29 | KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene, 2005, 24, 637-649. | 2.6 | 63 |
| 30 | T2 Mapping in Prostate Cancer. Investigative Radiology, 2019, 54, 146-152. | 3.5 | 63 |
| 31 | Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Molecular Cancer, 2014, 13, 214. | 7.9 | 62 |
| 32 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120. | 5.1 | 61 |
| 33 | Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Letters, 2004, 215, 209-220. | 3.2 | 54 |
| 34 | Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer, 2007, 109, 2016-2024. | 2.0 | 53 |
| 35 | Clinical Outcome of Patients with Lymph Node Positive Prostate Cancer after Radical Prostatectomy versus Androgen Deprivation. European Urology, 2002, 41, 628-634. | 0.9 | 52 |
| 36 | DNA methylation alterations in urothelial carcinoma. Cancer Biology and Therapy, 2006, 5, 993-1001. | 1.5 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | P53 accumulation in precursor lesions and early stages of bladder cancer. World Journal of Urology, 1994, 12, 79-83. | 1.2 | 50 |
| 38 | Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2020, 11, 364. | 2.2 | 50 |
| 39 | The Investigation of Hematuria. Deutsches Ärzteblatt International, 2018, 115, 801-807. | 0.6 | 48 |
| 40 | Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 368-380. | 0.9 | 48 |
| 41 | Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urological Research, 1995, 23, 293-300. | 1.5 | 47 |
| 42 | The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534. | 1.0 | 41 |
| 43 | A Natural Androgen Receptor Antagonist Induces Cellular Senescence in Prostate Cancer Cells. Molecular Endocrinology, 2014, 28, 1831-1840. | 3.7 | 36 |
| 44 | New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. Journal of Clinical Medicine, 2020, 9, 565. | 1.0 | 35 |
| 45 | Evidence from the â€˜PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)â€™ Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. Annals of Surgical Oncology, 2015, 22, 1032-1042. | 0.7 | 33 |
| 46 | First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. European Urology, 2022, 81, 266-271. | 0.9 | 33 |
| 47 | The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clinical Genitourinary Cancer, 2017, 15, 356-362. | 0.9 | 31 |
| 48 | Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs, 2013, 31, 1001-1007. | 1.2 | 30 |
| 49 | Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. Urologia Internationalis, 2018, 101, 16-24. | 0.6 | 28 |
| 50 | Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology, 2004, 63, 392-397. | 0.5 | 26 |
| 51 | Prostate Artery Embolization: Indication, Technique and Clinical Results. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2018, 190, 847-855. | 0.7 | 26 |
| 52 | Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World Journal of Urology, 2011, 29, 361-366. | 1.2 | 25 |
| 53 | Advances in renal cell carcinoma treatment. Therapeutic Advances in Urology, 2010, 2, 11-17. | 0.9 | 24 |
| 54 | Expression of theForkheadTranscription Factor FOXP1 is Associated with Tumor Grade and Ki67 Expression in Clear Cell Renal Cell Carcinoma. Cancer Investigation, 2011, 29, 123-129. | 0.6 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1171-1182. | 1.2 | 23 |
| 56 | Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiologica, 2010, 51, 581-589. | 0.5 | 22 |
| 57 | Risk factors for incidental prostate cancerâ€"who should not undergo vaporization of the prostate for benign prostate hyperplasia?. Prostate, 2011, 71, 1325-1331. | 1.2 | 22 |
| 58 | Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 99-104. | 0.8 | 21 |
| 59 | Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817. | 0.9 | 21 |
| 60 | Periâ€operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity scoreâ€weighted European multicentre study. BJU International, 2018, 121, 101-110. | 1.3 | 21 |
| 61 | Prostatic Artery Embolization with 250-Î¼m Spherical Polyzene-Coated Hydrogel Microspheres for Lower Urinary Tract Symptoms with Follow-up MR Imaging. Journal of Vascular and Interventional Radiology, 2018, 29, 1127-1137. | 0.2 | 21 |
| 62 | SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer, 2019, 107, 37-45. | 1.3 | 21 |
| 63 | A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. Oncology Research and Treatment, 2020, 43, 333-339. | 0.8 | 20 |
| 64 | FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers. International Urology and Nephrology, 2014, 46, 1769-1774. | 0.6 | 19 |
| 65 | Penile metastasis secondary to follicular thyroid carcinoma. Scandinavian Journal of Urology and Nephrology, 2004, 38, 253-255. | 1.4 | 18 |
| 66 | Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncology, 2020, 16, 2307-2328. | 1.1 | 17 |
| 67 | Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Research, 2008, 28, 2259-63. | 0.5 | 17 |
| 68 | Surgery for renal cell cancer extending into the inferior vena cava â€“ evaluation of survival and perioperative complications using a standardized classification system. BJU International, 2011, 108, 1439-1443. | 1.3 | 16 |
| 69 | Innate immune response of human epidermal keratinocytes and dermal fibroblasts to inÂvitro incubation of Trichophyton benhamiae <scp>DSM</scp> 6916. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1177-1188. | 1.3 | 16 |
| 70 | The androgen receptorâ€"lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells. Oncogene, 2022, 41, 943-959. | 2.6 | 16 |
| 71 | High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrology Dialysis Transplantation, 2016, 31, 1515-1522. | 0.4 | 14 |
| 72 | Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1757-1769. | 1.2 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Prostatic Artery Embolizationâ€"Anatomic Predictors of Technical Outcomes. Journal of Vascular and Interventional Radiology, 2020, 31, 378-387. | 0.2 | 14 |
| 74 | Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 581-581. | 0.8 | 14 |
| 75 | Anemia under Androgen Deprivation: Influence of Flutamide, Cyproteroneacetate and Orchiectomy on the Erythropoietin System. Hormone and Metabolic Research, 2005, 37, 89-93. | 0.7 | 13 |
| 76 | Placental Schistosoma haematobium infection in a German returnee from Malawi. Infection, 2014, 42, 1061-1064. | 2.3 | 13 |
| 77 | Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection. World Journal of Urology, 2019, 37, 2699-2705. | 1.2 | 13 |
| 78 | Primary Treatment of Ureteral Stones by New Multiline Lithotripter. Journal of Endourology, 1999, 13, 339-342. | 1.1 | 12 |
| 79 | SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. Cells, 2021, 10, 80. | 1.8 | 12 |
| 80 | Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.. Journal of Clinical Oncology, 2019, 37, 4524-4524. | 0.8 | 11 |
| 81 | Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 564-564. | 0.8 | 10 |
| 82 | Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH. British Journal of Cancer, 2014, 110, 2537-2543. | 2.9 | 9 |
| 83 | Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study. Urologia Internationalis, 2016, 96, 57-64. | 0.6 | 8 |
| 84 | Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased Donors. Transplantation Proceedings, 2021, 53, 1454-1461. | 0.3 | 8 |
| 85 | Antithetic hTERT Regulation by Androgens in Prostate Cancer Cells: hTERT Inhibition Is Mediated by the ING1 and ING2 Tumor Suppressors. Cancers, 2021, 13, 4025. | 1.7 | 8 |
| 86 | The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2. Oncogene, 2022, 41, 3263-3277. | 2.6 | 8 |
| 87 | Establishment of a Multicolour Fluorescence In Situ Hybridisation-based Assay for Subtyping of Renal Cell Tumours. European Urology, 2013, 64, 689-691. | 0.9 | 7 |
| 88 | A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 811-820. | 1.2 | 7 |
| 89 | High Detection Rate for Nonâ€"Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test. Clinical Genitourinary Cancer, 2020, 18, 210-221. | 0.9 | 7 |
| 90 | Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies. Translational Oncology, 2020, 13, 100801. | 1.7 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Everolimus after failure of one prior VEGF â€targeted therapy in metastatic renal cell carcinoma: Final results of the MARC â€2 trial. International Journal of Cancer, 2021, 148, 1685-1694. | 2.3 | 7 |
| 92 | An alternatively spliced KAI1 mRNA is expressed at low levels in human bladder cancers and bladder cancer cell lines and is not associated with invasive behaviour. Oncology Reports, 2007, 18, 1357-63. | 1.2 | 7 |
| 93 | Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. Journal of Clinical Oncology, 2022, 40, 2128-2137. | 0.8 | 7 |
| 94 | Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial. Oncology and Therapy, 2017, 5, 75-78. | 1.0 | 6 |
| 95 | Evaluation of Plasmatic Kisspetin-10 as a Biomarker for Malignancy and Subtype Differentiation in Small Renal Tumours. Urologia Internationalis, 2017, 98, 177-183. | 0.6 | 5 |
| 96 | Position Paper of the German Society for Interventional Radiology (DeGIR) on Prostatic Artery Embolization. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 835-846. | 0.7 | 5 |
| 97 | Prevalence and Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction in a Contemporary Series of Renal Transplant Recipients. Nephro-Urology Monthly, 2016, 8, e35497. | 0.0 | 5 |
| 98 | Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine, 2021, 10, 5339. | 1.0 | 5 |
| 99 | Clinical and Functional Results after Continent Cutaneous Urinary Diversion with the Ileal Double-T-Pouch. Urologia Internationalis, 2008, 80, 8-12. | 0.6 | 4 |
| 100 | Gigantic Suprapubic Lymphedema: A Case Study. World Journal of Men?s Health, 2016, 34, 148. | 1.7 | 4 |
| 101 | Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study).. Journal of Clinical Oncology, 2013, 31, TPS4591-TPS4591. | 0.8 | 4 |
| 102 | Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. European Urology Focus, 2022, 8, 1289-1299. | 1.6 | 4 |
| 103 | Wnt/Î²-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 5319. | 1.8 | 4 |
| 104 | Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 381, 329-338. | 1.4 | 3 |
| 105 | Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. International Urology and Nephrology, 2017, 49, 247-254. | 0.6 | 3 |
| 106 | Reply to Emre Karabay and Ä°lker TÄ±nayâ€™s Letter to the Editor re: Treatment of High-grade Nonâ€“muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial â€œNIMBUSâ€• Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066. European Urology, 2020, 78, e163-e164. | 0.9 | 3 |
| 107 | Re: Utilization and Outcomes of Minimally Invasive Radical Prostatectomy. European Urology, 2008, 54, 1439-1440. | 0.9 | 2 |
| 108 | Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study. Oncology Research and Treatment, 2019, 42, 57-66. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 2021, 13, 2594. | 1.7 | 2 |
| 110 | Influence of Prostate Artery Embolization on Different Qualities of Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction. European Urology Focus, 2022, 8, 1323-1330. | 1.6 | 2 |
| 111 | Reply to JÃ©rÃ´me Verine, Christophe Leboeuf and Philippe Ratajczak's Letter to the Editor re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a Multicolour Fluorescence In Situ Hybridisation-based Assay for Subtyping of Renal Cell Tumours. Eur Urol 2013;64:689â€“91. European Urology, 2014, 65, e71-e72. | 0.9 | 1 |
| 112 | High-grade Carcinoma of the Proximal Ureter With Negative Nephroureteroscopy Detected by a Positive FISH Test: A Rare Case Report. Urology Case Reports, 2015, 3, 167-169. | 0.1 | 1 |
| 113 | Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. Future Oncology, 2018, 14, 1023-1034. | 1.1 | 1 |
| 114 | Prospective evaluation study on the benefit of the simultaneous detection of seven sexually transmitted pathogens for the clinical management of patients suffering from sexually transmitted diseases. Journal of Laboratory Medicine, 2019, 43, 13-20. | 1.1 | 0 |
| 115 | Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. European Urology, 2021, 79, 429-430. | 0.9 | 0 |
| 116 | How to Deal with Renal Cell Carcinoma >7â€‰cm: Radical Surgery. European Urology Open Science, 2021, 33, 81-82. | 0.2 | 0 |
| 117 | In Reply. Deutsches Ärzteblatt International, 2019, 116, 192-193. | 0.6 | 0 |